Alnylam Pharmaceuticals (NASDAQ:ALNY) Upgraded at Freedom Capital

Freedom Capital upgraded shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) from a hold rating to a strong-buy rating in a research report released on Tuesday morning,Zacks.com reports.

ALNY has been the topic of several other reports. Jefferies Financial Group reduced their target price on Alnylam Pharmaceuticals from $550.00 to $549.00 and set a “buy” rating on the stock in a research report on Thursday, October 30th. Bank of America reaffirmed a “buy” rating on shares of Alnylam Pharmaceuticals in a research note on Thursday, February 12th. Oppenheimer started coverage on shares of Alnylam Pharmaceuticals in a research report on Wednesday, January 7th. They issued an “outperform” rating and a $500.00 target price on the stock. Raymond James Financial restated an “outperform” rating and issued a $472.00 target price on shares of Alnylam Pharmaceuticals in a report on Monday, January 12th. Finally, Chardan Capital cut their price target on shares of Alnylam Pharmaceuticals from $475.00 to $425.00 and set a “buy” rating on the stock in a research note on Friday, February 13th. One research analyst has rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and five have given a Hold rating to the stock. According to data from MarketBeat, Alnylam Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus price target of $477.96.

Alnylam Pharmaceuticals Stock Performance

Shares of ALNY opened at $339.37 on Tuesday. Alnylam Pharmaceuticals has a 1 year low of $205.87 and a 1 year high of $495.55. The company’s 50 day simple moving average is $368.11 and its 200 day simple moving average is $423.02. The company has a market capitalization of $45.01 billion, a price-to-earnings ratio of 198.46 and a beta of 0.35. The company has a debt-to-equity ratio of 1.28, a quick ratio of 2.71 and a current ratio of 2.76.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings results on Thursday, February 12th. The biopharmaceutical company reported $0.82 earnings per share for the quarter, missing the consensus estimate of $1.43 by ($0.61). Alnylam Pharmaceuticals had a net margin of 6.43% and a return on equity of 69.02%. The business had revenue of $1.10 billion during the quarter, compared to analyst estimates of $1.16 billion. During the same quarter last year, the firm posted ($0.65) earnings per share. The company’s revenue was up 84.9% on a year-over-year basis. On average, sell-side analysts predict that Alnylam Pharmaceuticals will post -1.7 EPS for the current year.

Insider Activity

In other Alnylam Pharmaceuticals news, EVP Pushkal Garg sold 2,242 shares of the business’s stock in a transaction that occurred on Friday, February 13th. The shares were sold at an average price of $310.08, for a total transaction of $695,199.36. Following the completion of the sale, the executive vice president directly owned 24,848 shares in the company, valued at $7,704,867.84. The trade was a 8.28% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Jeffrey V. Poulton sold 2,780 shares of the firm’s stock in a transaction on Monday, January 12th. The shares were sold at an average price of $362.87, for a total transaction of $1,008,778.60. Following the completion of the transaction, the executive vice president directly owned 57,465 shares in the company, valued at approximately $20,852,324.55. This represents a 4.61% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 36,578 shares of company stock valued at $12,416,105 over the last quarter. 1.50% of the stock is owned by insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the stock. Brighton Jones LLC purchased a new stake in shares of Alnylam Pharmaceuticals during the 4th quarter valued at about $243,000. Geneos Wealth Management Inc. boosted its holdings in Alnylam Pharmaceuticals by 372.3% in the 1st quarter. Geneos Wealth Management Inc. now owns 222 shares of the biopharmaceutical company’s stock worth $60,000 after acquiring an additional 175 shares during the period. Envestnet Portfolio Solutions Inc. grew its position in Alnylam Pharmaceuticals by 34.3% in the second quarter. Envestnet Portfolio Solutions Inc. now owns 1,164 shares of the biopharmaceutical company’s stock valued at $380,000 after acquiring an additional 297 shares in the last quarter. Cullen Frost Bankers Inc. grew its position in Alnylam Pharmaceuticals by 0.7% in the second quarter. Cullen Frost Bankers Inc. now owns 10,795 shares of the biopharmaceutical company’s stock valued at $3,520,000 after acquiring an additional 78 shares in the last quarter. Finally, Ethic Inc. raised its stake in shares of Alnylam Pharmaceuticals by 6.5% during the second quarter. Ethic Inc. now owns 2,176 shares of the biopharmaceutical company’s stock valued at $703,000 after purchasing an additional 133 shares during the period. Institutional investors and hedge funds own 92.97% of the company’s stock.

Alnylam Pharmaceuticals News Roundup

Here are the key news stories impacting Alnylam Pharmaceuticals this week:

• Positive Sentiment: Canaccord Genuity raised its price target to $429 and kept a buy rating, signaling meaningful upside versus the current quote. Canaccord price-target raise
• Positive Sentiment: HC Wainwright reaffirmed a “buy” and set a $510 price target (~50% above the current level), providing a bullish benchmark for upside expectations. HC Wainwright note
• Positive Sentiment: Freedom Capital upgraded ALNY from Hold to Strong-Buy, adding to positive analyst momentum. Freedom Capital upgrade
• Positive Sentiment: Large institutional buying reported in Q4 (notable stake increases by Guggenheim, Caisse, Schonfeld and AQR) suggests strong institutional conviction and supports liquidity/demand for the shares.
• Neutral Sentiment: Short-interest entries in the feed show zero/NaN and a 0.0 days-to-cover figure — this looks like a data/reporting artifact rather than new shorting pressure; treat as non-actionable until exchange-confirmed data appears.
• Neutral Sentiment: Analysts collectively trimmed some near-term targets but still express confidence in 2026 growth — mixed model adjustments rather than a broad sell-off. Analysts trim targets
• Negative Sentiment: Several insiders sold shares this week, including CEO Yvonne Greenstreet (~6,958 shares) and multiple senior executives (Kevin Fitzgerald, Pushkal Garg, others). Large, clustered insider sales can weigh on sentiment even if they are routine or pre-planned. CEO sale SEC filing
• Negative Sentiment: Chardan trimmed its price target to $425 (a modest downgrade relative to some peers), and ALNY’s most recent quarterly report showed an EPS miss (Feb. 12) despite strong revenue growth — reminders of execution/near-term margin risk. Chardan target cut

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.